MCK Already Compounds. This Deal Speeds It Up.
McKesson’s $2.25bn Precision deal adds clinical research heft to its fast-growing oncology segment.
August 30, 2026
APP Is Down 53%. The Business Grew 53%.
AppLovin’s stock slid in 2026 while fundamentals kept compounding. That gap is the trade.